Pembrolizumab (new indication: carcinoma of the esophagus or gastroesophageal junction, PD-L1 expression ≥ (CPS), 1st line, in combination with platinum- and fluoropyrimidine-based chemotherapy)

Subject:

• Active Substance: Pembrolizumab
• Name: Keytruda^®
• Therapeutic area: Carcinoma of the esophagus
• Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

• Start: 15.11.2021
• Final decision by G-BA: 05.05.2022

Final decision:

• a) Squamous cell carcinoma of the esophagus which is not amenable to curative treatment: Indication for a considerable additional benefit
• b1) HER2-negative adenocarcinoma of the esophagus which is not amenable to curative treatment: No additional benefit proved
• b2) HER2-positive adenocarcinoma of the esophagus or gastrointestinal junction which is not amenable to curative treatment: No additional benefit proved